Neuropsychopharmacology

TABLE 1

FROM:

Abnormal Glutamate Receptor Expression in the Medial Temporal Lobe in Schizophrenia and Mood Disorders

Monica Beneyto, Lars V Kristiansen, Akinwunmi Oni-Orisan, Robert E McCullumsmith and James H Meador-Woodruff

BACK TO ARTICLE

Table 1. Characterization of Subjects

  Schizophrenia Major depression Bipolar disorder Normal controls
n 15151515
Age (years)44.2 (25–62)46.4 (30–65)42.3 (25–61)48.1 (29–68)
Sex (male/female)9/69/69/69/6
Race13C, 2A15C14C, 1AA14C, 1AA
PMI (hours)33.7 (12–61)27.5 (7–47)32.5 (13–62)23.7 (8–42)
Tissue pH6.1 (5.8–6.6)6.2 (5.6–6.5)6.2 (5.8–6.5)6.3 (5.8–6.6)
Side of brain6 right, 9 left6 right, 9 left8 right, 7 left7 right, 8 left
Suicide4/157/159/150/15
EtOH usea 5/153/155/151/15
Medicationb 12/1514/1512/150/15
SSRI2/154/152/150/15
Lithium2/152/154/150/15
Antipsychotic12/150/156/150/15
Other MSc 1/150/158/150/15

 C, Caucasian; AA, African American; A, Asian; EtOH, ethanol; SSRI, selective serotonin reuptake inhibitor.

a History of active EtOH abuse or dependence at time of death.

b Treatment with psychotropic medication within 6 weeks of time of death.

c Other mood stabilizers: carbamazepine and valproic acid.

BACK TO ARTICLE